Public Partnerships Leverage regulatory validation and government funding to target government agencies, state health departments, and hospital networks seeking reliable, multiplex respiratory testing at the point of care. The NIH RADx award and FDA EUA for at-home tests provide credibility to pursue tenders, programs, and large-scale procurements while opening doors to public health initiatives and national deployment opportunities.

Workplace Expansion Position the technology as a way to extend health services beyond clinic walls into the workplace, schools, and community settings. Target employers with corporate wellness programs, school districts with on-site testing, and community health partners to drive adoption of rapid, portable molecular testing.

Fast Results Highlight the rapid thirty-minute turnaround to improve patient throughput in emergency departments, urgent care, and long-term care facilities, enabling clinicians to make faster decisions and reduce bottlenecks. Propose integration with existing clinician workflows and digital health platforms to maximize adoption.

Home Testing Explore direct-to-consumer and partner channels for the OTC at-home molecular COVID-19 test, including pharmacies, retailers, insurers, and telehealth platforms. This can complement enterprise testing programs and create a blended offering for population health management, while ensuring regulatory compliance and user support.

Strategic Partnerships Leverage the NIH RADx validation and regulatory momentum to attract strategic partnerships with larger diagnostics firms, contract manufacturers, and health systems seeking scalable POCT solutions. Emphasize a flexible manufacturing and distribution plan to meet multi-site deployments and ongoing demand as government programs evolve.